Avrobio scores $60 mln Series B
Cambridge, Massachusetts-based Avrobio, a developer of gene therapies for rare diseases, has closed $60 million in Series B financing. Cormorant Asset Management and Surveyor Capital led the round with participation from other investors that included Aisling, Brace Pharma Capital, Eventide Asset Management, Morningside, Atlas Venture, SV Health Investors and Clarus Ventures.
1 February 2018•1 min read
